These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27771632)

  • 41. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Prevots DR; Burr RK; Sutter RW; Murphy TV;
    MMWR Recomm Rep; 2000 May; 49(RR-5):1-22; quiz CE1-7. PubMed ID: 15580728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Inactivated poliovirus vaccines: an inevitable choice for eliminating poliomyelitis].
    Vidor JD; Jean-Denis S
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1021-1031. PubMed ID: 28057103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polio eradication: next steps and future challenges.
    Zambon M; Martin J
    Euro Surveill; 2018 Nov; 23(47):. PubMed ID: 30482261
    [No Abstract]   [Full Text] [Related]  

  • 44. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.
    Thompson KM; Duintjer Tebbens RJ
    Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox.
    Heinsbroek E; Ruitenberg EJ
    Vaccine; 2010 May; 28(22):3778-83. PubMed ID: 20362626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The perspective of global eradication of poliomyelitis].
    Knolle H; Egli A; Candrian U
    Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The polio-eradication programme and issues of the end game.
    Minor PD
    J Gen Virol; 2012 Mar; 93(Pt 3):457-474. PubMed ID: 22128250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
    Thompson KM; Kalkowska DA
    Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
    [No Abstract]   [Full Text] [Related]  

  • 49. The golden jubilee of vaccination against poliomyelitis.
    John TJ
    Indian J Med Res; 2004 Jan; 119(1):1-17. PubMed ID: 14997988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Challenge of Global Poliomyelitis Eradication.
    Garon JR; Cochi SL; Orenstein WA
    Infect Dis Clin North Am; 2015 Dec; 29(4):651-65. PubMed ID: 26610419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polio control after certification: major issues outstanding.
    Fine PE; Oblapenko G; Sutter RW
    Bull World Health Organ; 2004 Jan; 82(1):47-52. PubMed ID: 15106300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poliomyelitis: eradication in sight.
    Melnick JL
    Epidemiol Infect; 1992 Feb; 108(1):1-18. PubMed ID: 1547830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Possible global strategies for stopping polio vaccination and how they could be harmonized.
    Cochi SL; Sutter RW; Aylward RB
    Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame.
    Zipursky S; Patel M; Farrell M; Gonzalez AR; Kachra T; Folly Y; Kurji F; Veira CL; Wootton E; Hampton LM
    J Infect Dis; 2017 Jul; 216(suppl_1):S15-S23. PubMed ID: 28838203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiology of poliomyelitis--options and update.
    Dutta A
    Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
    Tevi-Benissan C; Okeibunor J; du Châtellier GM; Assefa A; Biey JN; Cheikh D; Eshetu M; Anya BP; Dao H; Nasir Y; Akanmori BD; Mihigo R
    J Infect Dis; 2017 Jul; 216(suppl_1):S66-S75. PubMed ID: 28838178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.